Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) was upgraded by equities researchers at StockNews.com from a "sell" rating to a "hold" rating in a note issued to investors on Wednesday.
A number of other equities research analysts have also recently commented on the stock. HC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Abeona Therapeutics in a research note on Thursday, October 31st. Cantor Fitzgerald reiterated an "overweight" rating and issued a $18.00 price objective on shares of Abeona Therapeutics in a report on Tuesday, October 29th.
Get Our Latest Research Report on ABEO
Abeona Therapeutics Trading Down 2.4 %
Shares of NASDAQ:ABEO traded down $0.14 during midday trading on Wednesday, reaching $5.75. The company's stock had a trading volume of 215,612 shares, compared to its average volume of 432,289. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The firm has a 50 day moving average price of $6.18 and a two-hundred day moving average price of $5.27. The firm has a market capitalization of $249.95 million, a price-to-earnings ratio of -2.19 and a beta of 1.52. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $9.01.
Institutional Investors Weigh In On Abeona Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rosalind Advisors Inc. acquired a new stake in Abeona Therapeutics in the second quarter valued at approximately $7,420,000. Western Standard LLC raised its stake in shares of Abeona Therapeutics by 68.5% during the first quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company's stock valued at $9,871,000 after acquiring an additional 553,377 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company's stock worth $2,134,000 after purchasing an additional 429,456 shares in the last quarter. Simplify Asset Management Inc. purchased a new stake in Abeona Therapeutics during the 2nd quarter valued at about $1,732,000. Finally, abrdn plc boosted its holdings in shares of Abeona Therapeutics by 158.8% during the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company's stock valued at $2,067,000 after acquiring an additional 200,647 shares during the last quarter. Institutional investors own 80.56% of the company's stock.
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Stories
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
